Benefit-risk assessment for metastatic pancreatic cancer

A quantitative assessment was conducted to evaluate the benefit-risk balance of a specific treatment for metastatic pancreatic cancer. This investigation focused on integrating key efficacy outcomes such as overall survival, distant and local tumor progression, with safety outcomes such as occurrences of severe toxicities. The results offered robust empirical evidence, supporting the therapy's superior efficacy and safety profile compared to competitors. Such research is crucial for informing prescription guidelines and conducting comprehensive cost-effectiveness evaluations.